Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease (DANCE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01983449|
Recruitment Status : Completed
First Posted : November 14, 2013
Last Update Posted : March 8, 2018
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
To assess the safety and effectiveness of adventitial deposition of the Study Drug in reducing inflammation and restenosis in patients with clinical evidence of claudication or critical limb ischemia and an angiographically significant lesion in the superficial femoral and/or popliteal arteries.
Study Drug and Dose: Dexamethasone Sodium Phosphate Injection, USP, 4 mg/ml, with dilute contrast (17%) administered to the adventitia in a dose of 1.6 mg per cm of desired vessel treatment length.
|Condition or disease||Intervention/treatment||Phase|
|Peripheral Arterial Diseases||Drug: Dexamethasone Sodium Phosphate Injection, USP||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||285 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization|
|Study Start Date :||November 2013|
|Actual Primary Completion Date :||December 2016|
|Actual Study Completion Date :||January 2018|
Experimental: Adventitial Dexamethasone
In patients receiving either angioplasty or atherectomy-based revascularization (pre-stratified to each by 50% of the total study), dexamethasone will be delivered to the adventitia following revascularization.
Drug: Dexamethasone Sodium Phosphate Injection, USP
Adventitial infusion of dexamethasone after angioplasty or atherectomy-based revascularization of the superficial femoral or popliteal artery.
- MALE-POD [ Time Frame: 30 days ]Acute safety safety outcomes will be determined by evaluating the type, frequency, severity, and relatedness of Major Adverse Limb Events or Peri-Operative Death (MALE+POD) within 30 days from the procedure for all subjects.
- Duplex ultrasound index lesion binary restenosis [ Time Frame: 6 months ]Binary restenosis will be judged by core laboratory interpretation with peak systolic velocity ratio (PSVR) greater than 2.4.
- Duplex ultrasound index lesion binary restenosis [ Time Frame: 12 months ]Binary restenosis will be judged by core laboratory interpretation with peak systolic velocity ratio (PSVR) greater than 2.4.
- Long term safety [ Time Frame: 30 days to 6 months ]Long term safety outcomes that occur after 30 days through 6 months post-procedure will be determined by evaluating adverse events.
- Duplex ultrasound index lesion flow limiting restenosis [ Time Frame: 6 and 12 months ]Flow limiting restenosis will be judged by core laboratory as PSVR>4.0.
- Change in inflammatory biomarkers [ Time Frame: Baseline and 24 hours ]Change in inflammatory biomarkers will be measured with a panel of biomarkers in 1/3 of patients.
- Vascular patency [ Time Frame: 6, 12, 18 and 24 months ]Target lesion revascularization (TLR) rate, target extremity revascularization (TER) rate, limb salvage rate and primary patency (PSVR≤2.4 and no TLR) at 6, 12, 18 and 24 months. Note: provisional stenting performed during the index procedure shall not be considered to be TLR, TER or loss of primary patency.
- Clinical outcome measures [ Time Frame: 1, 6, 12, 18 and 24 months ]Modified Walking Impairment Questionnaire, Ankle-Brachial Index, Rutherford Score.
- Infusion Technical Success [ Time Frame: Intraprocedural ]Distribution grade around infusion sites.
- Procedural Success [ Time Frame: Intraprocedural ]Establishment of antegrade flow with residual stenosis of <30% by angiogram.
- Healthcare Economics [ Time Frame: 30 days ]Number of return visits and hospitalizations, time from index procedure to required revascularization and number of index-lesion-related readmissions within 30 days will be measured.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Male or non-pregnant female ≥18 years of age
- Rutherford Clinical Category 2-4
- Clinical diagnosis of PAD requiring revascularization, secondary to atherosclerosis affecting a lower limb
- Patient is willing to provide informed consent and comply with the required follow up visits, testing schedule, and medication regimen
- De novo or nonstented restenotic lesions >90 days from prior angioplasty and/or atherectomy, at least 3 cm from any previously placed stent or vascular surgery site
- >70% diameter stenosis up to 15 cm in total length (with no greater than 3 cm length of contiguous intervening normal artery) in the superficial femoral and/or popliteal artery (between the profunda and tibioperoneal trunk)
- Reference vessel diameter ≥3mm and ≤ 8mm
- Successful wire crossing of lesion
- A patent artery proximal to the index lesion free from significant stenosis (significant stenosis is defined as >50% in iliac or >30% stenosis in common femoral artery) as confirmed by angiography (treatment of target lesion after successful treatment of iliac or common femoral artery lesions is acceptable)
- Pregnant, nursing or planning on becoming pregnant in < 2 years
- Life expectancy of <2 years
- Known active malignancy
- History of solid organ transplantation
- Patient actively participating in another investigational device or drug study
- History of hemorrhagic stroke within 3 months
- Previous or planned surgical or interventional procedure within 30 days of index procedure
- Chronic renal insufficiency with eGFR <29
- Prior bypass surgery, stenting of the target lesion
- Inability to take required study medications
- Contra-indication or known hypersensitivity to dexamethasone sodium phosphate, contrast media, or Physician prescribed antiplatelet regimen as indicated
- Systemic fungal infection
- Anticipated use of IIb/IIIa inhibitor prior to index lesion treatment
- Acute or sub-acute thrombus, acute vessel occlusion or sudden symptom onset
- Acute limb ischemia
- Prior participation of the index limb in the current study (contralateral treatment is allowed)
- Inability to ambulate (e.g. from prior ipsilateral or contralateral amputation)
- Patient is receiving steroids already, however locally acting inhaled steroids for asthma treatment do not exclude patients from the trial
- Lesions extending into the trifurcation or above the profunda
- Heavy eccentric or moderate circumferential calcification at index lesion, which in the judgment of the investigator would prevent penetration of the Micro-Infusion Catheter needle through the vessel wall
- Lesion length is >15 cm as measured from proximal normal vessel to distal normal vessel, or there is no normal proximal arterial segment in which duplex ultrasound velocity ratios can be measured
- Inadequate distal outflow defined as absence of at least one patent tibial artery (no lesion >50% stenosis) with flow into the foot
- Use of adjunctive therapies other than angioplasty, atherectomy (mechanical or laser) or bare metal stenting (i.e. scoring/cutting balloon, drug-eluting stent, drug-coated balloon, cryoplasty, etc.)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01983449
|Principal Investigator:||Mahmood Razavi, MD||St. Joseph's Vascular Institute|
|Responsible Party:||Mercator MedSystems, Inc.|
|Other Study ID Numbers:||
1142183 ( Other Identifier: Western IRB )
|First Posted:||November 14, 2013 Key Record Dates|
|Last Update Posted:||March 8, 2018|
|Last Verified:||March 2018|
Peripheral Artery Disease
Peripheral Arterial Disease
Peripheral Vascular Diseases
Arterial Occlusive Diseases
Peripheral Nervous System Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Molecular Mechanisms of Pharmacological Action